scispace - formally typeset
S

Scott A. Hollingsworth

Researcher at Merck & Co.

Publications -  35
Citations -  2376

Scott A. Hollingsworth is an academic researcher from Merck & Co.. The author has contributed to research in topics: G protein-coupled receptor & Chemistry. The author has an hindex of 16, co-authored 31 publications receiving 1305 citations. Previous affiliations of Scott A. Hollingsworth include Oregon State University & Stanford University.

Papers
More filters
Journal ArticleDOI

Molecular Dynamics Simulation for All.

Scott A. Hollingsworth, +1 more
- 19 Sep 2018 - 
TL;DR: The types of information molecular dynamics simulations can provide and the ways in which they typically motivate further experimental work are described.
Journal ArticleDOI

Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex

TL;DR: The structure of the CB1-Gi signaling complex bound to the highly potent agonist MDMB-Fubinaca (FUB) is presented, which compose the structural framework to explain CB1 activation by different classes of ligands and provide insights into the G protein coupling and selectivity mechanisms adopted by the receptor.
Journal ArticleDOI

A fresh look at the Ramachandran plot and the occurrence of standard structures in proteins.

TL;DR: High-fidelity conformational information is used to explore novel ways to convey some of the basic aspects of the Ramachandran plot and of protein conformation to highlight the pressing need for a standard nomenclature for peptide conformation.
Journal ArticleDOI

Molecular mechanism of GPCR-mediated arrestin activation

TL;DR: The results, which suggest that diverse receptor binding modes can activate arrestin, provide a structural foundation for the design of functionally selective (‘biased’) GPCR-targeted ligands with desired effects on arrestin signalling.
Journal ArticleDOI

How GPCR Phosphorylation Patterns Orchestrate Arrestin-Mediated Signaling

TL;DR: The structural basis for the long-standing "barcode" hypothesis is revealed and has important implications for design of functionally selective GPCR-targeted drugs.